CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience

View Full Paper

Ask AI

Bookmark

Discussion

Retrospective cohort study reveals higher recurrent thromboembolism in APS patients treated with DOACs than VKAs, suggesting caution in their use.

Patients treated with direct oral anticoagulants had a higher rate of recurrent thromboembolism events compared to those on vitamin K antagonists.
The study involved 157 antiphospholipid syndrome patients over a median follow-up of 150 months to assess anticoagulant efficacy and safety.
Significant differences in thromboembolism types were observed, with DOAC patients having more venous thrombosis and fewer arterial thrombosis cases.
No major bleeding differences were found between treatment groups, indicating comparable safety profiles despite efficacy differences.

A 2025 study studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Retrospective cohort study reveals higher recurrent thromboembolism in APS patients treated with DOACs than VKAs, suggesting caution in their use.

Patients treated with direct oral anticoagulants had a higher rate of recurrent thromboembolism events compared to those on vitamin K antagonists.
The study involved 157 antiphospholipid syndrome patients over a median follow-up of 150 months to assess anticoagulant efficacy and safety.
Significant differences in thromboembolism types were observed, with DOAC patients having more venous thrombosis and fewer arterial thrombosis cases.
No major bleeding differences were found between treatment groups, indicating comparable safety profiles despite efficacy differences.

A 2025 study studied this question.

View Full Paper

Ask AI

Bookmark